The discovery of CCR3/H1 dual antagonists with reduced hERG risk

Abstract A series of dual CCR3/H 1 antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to deliver a compound suitable for clinical evaluation.